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Abstract The rapid determination of the presence of direct oral anticoagulants (DOACs) in a
patient remains a major challenge in emergency medicine and for rapid medical
treatment decisions. All DOACs are excreted into urine. A sensitive and speciﬁc point-of-
care test has been developed to determine whether they are present in patient urine
samples. This prospective multicenter study aimed to demonstrate at least 95% correct
positive and negative predictive results for factor Xa and thrombin inhibitors in urine
samples using DOAC Dipstick pads compared with liquid chromatography-tandem
mass spectrometry (LC-MS/MS) (NCT03182829). Nine hundred and fourteen subjects
were included and 880 were evaluated per protocol (factor Xa inhibitors apixaban,
edoxaban, and rivaroxaban: n¼451, thrombin inhibitor dabigatran: n¼ 429) at 18
centers. The sensitivity, speciﬁcity, accuracy, and predictive values and agreement
between methods for determination of factor Xa inhibitors were at least noninferior to
95%with a 0.5%margin and of thrombin inhibitor superior to 97.5%. These results were
compared with LC-MS/MS results in the intention-to-analyze cohort (all p<0.05). The
receiver operating curve showed c-values of 0.989 (factor Xa inhibitors) and 0.995
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Introduction
Direct oral anticoagulants (DOACs) have become the pre-
ferred treatment for nonvalvular atrial ﬁbrillation and ve-
nous thromboembolism.1,2 In emergency situations, DOACs
may need to be detected quickly, but this is not always
feasible; thus, conﬁrmation of the presence or absence of
DOACs remains a major challenge.3–5 Various tests are in
different stages of development.6–8 Emergency situations
with a need for point-of-care testing for the presence or
absence of DOACs include emergent or urgent major surgical
interventions, clinically relevant bleeding, or thrombotic
episodes with known or unknown anticoagulant therapy,
as well as the evaluation of unconscious patients or those
unable to inform clinicians about their anticoagulant thera-
py.9,10 Knowledge of the presence of a DOAC may inform use
of expensive reversal agents, whichwould not be indicated in
a patient without detectable DOAC exposure.
The in vitro diagnostic DOACDipstick was developed based
onthe rationale thatDOACsareexcreted intourine.11FactorXa
inhibitors and thrombin inhibitors are detected on different
DOAC Dipstick pads, each containing immobilized reagents
that speciﬁcally interact with the respective DOAC. Matrix
plasma proteins and cells are not present in urine samples,
unlike in blood or plasma, so cannot interact with DOACs
during the test and interferewith the DOAC Dipstick results.12
Amulticenter studywasconducted toassess theaccuracyof
the test in detecting direct oral factor Xa inhibitors (DXI) and
direct oral thrombin inhibitor dabigatran (DTI) in urine sam-
ples taken fromDOAC-treatedpatients. Testingwasperformed
in an actual point-of-care setting and color identiﬁcation
results were compared with liquid chromatography-tandem
mass spectrometry (LC-MS/MS) from urine samples.
Subjects and Methods
Design of the Study
In this prospective, open-label, controlled, nonrandomized,
multicenter study performed in Germany, subjects treated
with a DXI (apixaban, edoxaban, and rivaroxaban) or the DTI
dabigatran were included (NCT03182829). The DOAC Dip-
stick contains two separate pads for testing DXI and DTI. The
reagents that are immobilized on the pads are speciﬁc for DXI
or DTI and do not interact with each other. Therefore, the
thrombin pad serves as a negative control for the factor Xa
inhibitor test and vice versa.7 We did not include a group of
subjects not taking any DOAC.
Inclusion criteriawere: (1) full understanding of the study
and ability to follow the instructions, (2) signed and dated
written informed consent, (3) age 18 years, and (4) therapy
with either apixaban, edoxaban, rivaroxaban, or dabigatran
for at least 1 week. Exclusion criteria were inability to
provide urine samples, inability to understand the informed
consent, and severemental disability. The study protocolwas
approved by the primary ethics committee and the local
ethics committees of the participating centers (see section
‘‘Participating Centers’’ below) according to the Declaration
of Helsinki 1964. Subjects were included in the study after
they signed the informed consent form.
The subjects were recruited from 18 outpatient care units
specialized in oral anticoagulation. The date and time of their
last DOAC intake before urine collection was recorded and
subjects were asked to provide a urine sample in a propylene
container (100mL container with integrated transfer unit for
closed urine transfer in the V-urine vacuum system, with lid
assembled and safety label; Sarstedt AG, Nuermbrecht,
Germany). Demographic data (age, sex, and body weight),
DOAC type, dose and start date of DOAC therapy, indication
for anticoagulation, additional diseases relevant to DOAC
therapy, and additionalmedication relevant to DOAC therapy
were documented by the study personnel in the case report
form. The barcode of patient’s urine sample was attached to
the case report form for patient identiﬁcation.
Methods
Preparation of Urine Samples
Urine samples (4mL) were transferred into polyethylene tere-
phthalate tubes (V-Monovette Urine Z 4mL, Sarstedt AG) using
plastic syringes. The DOAC Dipstick test was performed on the
urine sample at the time of collection by site personnel as
describedbelow.Next, barcodeswere attached to the duplicate
samples and recorded in the case report form. The samples
were frozen immediately at –25°C, transferred without inter-
rupting the cold chain to the central laboratory (MVZ Limbach
and colleagues, Heidelberg, Germany) for LC-MS/MS analysis.
Performance of DOAC Dipstick Test
The test procedure has been described in detail previously.7
In short, the test strip is dipped into urine or control samples
for 2 to 3 seconds until all test pads are covered by urine.
Then, the test strip is placed on a ﬂat surface at room
temperature with the pads facing upwards. Pads are left
for 10minutes without contact with the table or other
surfaces. The results are then compared visually with the
reference scale (►Supplementary Fig. S1, available in the
online version) attached to the test strip container.
Site observers at each center had to pass a standardized
training program in the identiﬁcation of test pad colors during
the initiation visit. The visualized colors were documented on
the scheme in the case report form. The rating scale contained
(thrombin inhibitor). Visual evaluation of the factor Xa and thrombin inhibitor pads was
not different between centers. Qualitative determination of both types of DOACs was
accurate using the DOAC Dipstick compared with using LC-MS/MS. The high predictive
values may impact laboratory and clinical decision-making processes.
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the following possibilities: negative, positive þ, and positive
þþ for the factor Xa and thrombin inhibitor pads, normal and
abnormal for the urine color pad, and low, normal þ, and
normal þþ for the creatinine pad (►Supplementary Fig. S1,
available in the online version). The cutoff of pads of creatinine
was 0.25 g/L for “low” versus “normal” that corresponds to
about 30mL/min creatinine clearance. Site personnel with
known red-green blindness cannot perform the test. After
interpreting the result, the test strips were discarded.
Liquid Chromatography-Mass Spectrometry of DOACs
in Urine
LC-MS/MS was performed as previously described.7,13 The
lower limit for quantifying DOACs was<4 ng/mL. The DOAC
concentration in urine of subjects with chronic use of DOACs
is 10- to 50-fold higher than in plasma.11–13 The threshold of
30 ng/mL in urine for positivity assumes that, in subjects
with chronic use of DOAC, urine levels of the drug of interest
are always above the levels in plasma. The 30 ng/mL thresh-
old in plasma has been proposed for safe hemostasis by
several experts.14–16 Using the same threshold for a positive
result in urine samples was therefore a very conservative
approach in the present study.
Further, if LC-MS/MS determined the level of one of the
four DOACs to be30 ng/mL, a positive visual evaluation of
the appropriate pad was counted as correct positive and a
negative visual evaluation was counted as false negative,
respectively (►Fig. 1). If LC-MS/MS determined the DOAC to
be present at a concentration of<30 ng/mL, both the Xa pad
and the thrombin inhibitor pad should have been interpreted
as negative; thus, a negative visual evaluationwas counted as
correct negative and a positive visual evaluation as false
positive, respectively (►Fig. 1).
Endpoints
The primary endpoint of the study was to analyze the true
positive and true negative rate of the factor Xa inhibitor and
thrombin inhibitor DOAC Dipstick test compared with the
results obtained by LC-MS/MS.
Intercenter variability was analyzed because visual iden-
tiﬁcation of the test pad colors could not be quantitatively
analyzed.
Documentation of the Data
Biographic data, indication for DOAC therapy, DOAC taken,
inclusion and exclusion criteria, concomitant diagnoses and
medications, visual evaluation of the DOAC Dipstick test, and
urine transfer to speciﬁc tubes for LS-MS/MS analysis were
documented in a speciﬁc case report form. Two documenta-
tion assistants, following the four-eye principle, entered data
into Excel 2017. Datawere then transferred to SAS release 9.4
(see below) for statistical analysis.
Sample Size Determination
The study hypothesis was that the proportions of correct
positive and correct negative test results using the DOAC
Dipstick would be at least 95% assuming an equivalence limit
of 2.5% conducting a one-sided test with a power of 0.80 and
a signiﬁcance level of p<0.05. The sample size calculation for
a binomial test used the ONESAMPLEFREQ statement in the
SAS procedure SAS POWER.17 This required 384 evaluable
subjects per DXI and DTI group. To account for a predicted
dropout rate of 12%, we increased the sample size to n¼440
subjects per test group (SAS procedure PROC POWER, SAS
Institute Inc., Cary, North Carolina, United States, release 9.4).
If the level of signiﬁcance was obtained for sensitivity,
speciﬁcity, accuracy, negative or positive predictive value,
and agreement betweenmethods (kappa value), then testing
was conducted using a proportion of 97.5%. If any parameter
was not signiﬁcant, a noninferiority test was added including
a margin of equivalence of 0.5% that was regarded as clini-
cally acceptable.
Quantitative variableswere presented asmean values and
standard deviations or as mean values and 95% conﬁdence
intervals. The DOAC concentrations were presented as
medians and quartiles. Qualitative data were presented as
absolute and relative frequencies. “Positiveþ ” and “positive
þþ” results for factor Xa and thrombin inhibitors were
combined into “positive” for the analysis.
McNemar tests were conducted to compare the sensitivi-
ty, speciﬁcity, accuracy, negative predictive value, positive
predictive value, and the probability of detecting both med-
ications. Thekappa coefﬁcientswere calculated to determine
the strength of agreement between DOAC Dipstick and LC-
MS/MS methods. The intercenter variability was assessed
with the chi-square test. Results were considered signiﬁcant
at a p-value of<0.05.
Results
During the study period (August 2018–April 2019), 914
subjects were included, of which 880 subjects were evalu-
able for the analysis (451 in the DXI group and 429 in the DTI
group) (►Table 1). The numbers and reasons for dropout are
given in ►Fig. 1.
Demographic Data
Demographic data, the number of subjects treated with
apixaban, edoxaban, rivaroxaban (DXI group), and dabiga-
tran (DTI group), comorbidities, and comedications are listed
in ►Table 1.
Results of LC-MS/MS
The urine concentrations of apixaban, edoxaban, rivaroxa-
ban, and dabigatran are given in►Table 2. Levels determined
by LC-MS/MS are higher in urine compared with those
expected in plasma.
Primary Endpoint
Per-Protocol Evaluation
Factor Xa inhibitor DOAC Dipstick test: In the DXI group, the
factor Xa inhibitor pad was evaluated in 435/452 cases
(96.2%) as correct positive and in 17/452 cases (3.8%) as false
negative after comparison with the LC-MS/MS results. In the
DTI group, the factor Xa inhibitor pad was evaluated in 421/
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428 cases (98.4%) as correct negative and in 7/428 (1.6%)
cases as false positive after comparison with the LC-MS/MS
results (►Table 3).
Thrombin inhibitor DOAC Dipstick test: In the DTI group,
the thrombin inhibitor pad was evaluated in 427/429 cases
(99.5%) as correct positive and in 2/429 cases (0.5%) as false
negative after comparison with the LC-MS/MS results. In the
DXI group, the thrombin inhibitor pad was evaluated in 448/
451 cases (99.3%) as correct negative and in 3/451 cases
(0.7%) as false positive after comparison with the LC-MS/MS
results (►Table 4).
The speciﬁcity, accuracy, and positive predictive value
were signiﬁcant at 95% (p<0.002) and the sensitivity and
negative predictive value were signiﬁcantly noninferior at a
Eligible subjects
(n = 911)
Subjects included
(n = 880)
Liquid chromatography
mass spectrometry
Urine sample
F Xa inhibitor
Api, Edo, Riva
F IIa inhibitor
Dabi
correct
neg.
correct
pos.
pos.
(correct)
neg.
(false)
pos.
(false)
neg.
(correct)
pos.
(correct)
neg.
(false)
pos.
(false)
neg.
(correct)
correct
neg.
correct
pos.
F IIa inhibitor
Dabi
F Xa inhibitor
Api, Edo, Riva
Pad 3:
F Xa inhibitor
Pad 4:
F IIa inhibitor
Pad 4:
F IIa inhibitor
Pad 3:
F Xa inhibitor
Urine sample
DOAC Dipstick DOAC Dipstick
Group A
Intake
Factor Xa inhibitor
(n = 451)
Group B
Intake
Factor IIa inhibitor
(n = 429)
All subjects
(n = 914)
Exclusion (3)
• Withdrawn consent (1)
• Inclusion after study close (2)
Exclusion criteria (31)
• On therapy < 7d (11)
• Non compliant (10)
• Eligibility not fulfilled (3)
• No urine sample (1)
• No assessment of pads (3)
• Urine colour abnormal (3)
Fig. 1 Study ﬂowchart showing the subjects included in the study and direct oral anticoagulant (DOAC) determination in urine samples using
the DOAC Dipstick test and liquid chromatography-tandemmass spectrometry (LC-MS/MS) to detect correct and false visual evaluation of factor
Xa inhibitor pads and thrombin inhibitor pads after incubation in urine samples taken from subjects in the oral direct factor Xa inhibitor (DXI)
group and the oral thrombin inhibitor (DTI) group. Api, apixaban; Edo, edoxaban; Riva, rivaroxaban; Dabi, dabigatran; F, factor.
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proportion of 95% including the 0.5% margin (p<0.04). The
agreement (kappa value) between results of the factor Xa
inhibitor pad and LC-MS/MS was 0.945 (►Table 5).
The results for sensitivity, speciﬁcity, accuracy, and nega-
tive and positive predictive visual evaluation of the thrombin
inhibitor pad were signiﬁcant at a proportion of 97.5%
(p<0.001). The kappa value was 0.987 (►Table 5).
The individual concentrations of the DOACs determined
by LS-MS/MS are reported in ►Supplementary Tables S1
(DXI group) and S2 (DTI group) (available in the online
version) for subjects in whom observers assessed colors of
pad 3 (factor Xa inhibitors) and pad 4 (thrombin inhibitor) as
false negative or false positive. The urine color pad was
observed as “normal” in these cases. Therefore, the observers
had probably interpreted the colors of the dipstick
incorrectly.
Table 1 Demographic data, concomitant diseases, and
concomitant medication (multiple designations) of patients of
DXI group and of DTI group
DXI group DTI group
Demographic data
n 451 429
Sex, male/female, n/n 250/201 291/138
Age (y), mean (SD) 67.3 (14.1) 70.6 (11.6)
Height (cm), mean (SD) 172.4 (9.9) 173.7 (10.3)
BMI (kg/m2), mean (SD) 28.3 (5.4) 27.6 (4.6)
Apixaban, n (%) 170 (37.7)
Edoxaban, n (%) 131 (29.0)
Rivaroxaban, n (%) 150 (33.3)
Dabigatran, n (%) 429 (100)
Atrial ﬁbrillation, n(%) 287 (63.6) 391 (91.1)
VTE, n (%) 136 (30.2) 17 (4.0)
Other indications, n (%) 28 (6.2) 21 (4.9)
Secondary diagnoses n N
Hypertension 74 60
Diabetes 20 13
Cardiac insufﬁciency 14 20
Ischemic stroke 18 27
Malignancy 18 15
Thrombophilia 32 3
Thrombotic disease 44 13
Hemorrhagic disorder 8 7
Rhythmologic intervention 111 125
Cardiovascular disease 104 141
Aortic stenosis 32 58
Metabolic disease 31 39
Neurologic disease 5 36
Renal insufﬁciency 19 7
Other disease 85 83
Pulmonary disease 7 15
Other medication
Platelet inhibitors 72 66
Antidiabetic drugs 19 23
Antihypertonic drugs 239 205
Antiarrhythmic drugs 12 47
Diuretic drugs 43 56
Lipid lowering drugs 37 55
Unspeciﬁc cardiac drugs 13 23
Chemotherapy 11 8
Hormones 42 31
Gastrointestinal drugs 33 32
Neurological drugs 18 32
Other medications 64 56
Abbreviations: BMI, body mass index; DTI, direct thrombin inhibitor;
DXI, direct factor Xa inhibitor; SD, standard deviation; VTE, venous
thromboembolism.
Table 2 The concentrations of apixaban, edoxaban, rivaroxaban,
and dabigatran in patient urine samples are shown as median
values together with 5th and 95th percentiles
n Median
(ng/mL)
5th percentile
(ng/mL)
95th percentile
(ng/mL)
Apixaban 170 648 89 3,213
Edoxaban 131 8,785 417 71,203
Rivaroxaban 150 1,903 248 8,160
Dabigatran 429 4,206 515 21,642
Table 3 Visual interpretationof the factor Xa inhibitorpad (pad3)
after incubation in urine samples from subjects in the direct oral
factor Xa inhibitor (DXI) group and the direct oral thrombin
inhibitor (DTI) group compared with LC-MS/MS results
Factor Xa inhibitor pad
LC-MS/MS result DOAC Dipstick result
Positive Negative
Positive 452 435 17
Negative 428 7 421
Sum 880 442 438
Abbreviations: DOAC, direct oral anticoagulant; LC-MS/MS, liquid
chromatography-tandem mass spectrometry.
Table 4 Visual evaluation of thrombin inhibitor pad (pad 4)
after incubation in urine samples from subjects in the direct oral
factor Xa inhibitor (DXI) group and the direct oral thrombin
inhibitor (DTI) group compared with LC-MS/MS results
Thrombin inhibitor pad
LC-MS/MS result DOAC Dipstick result
Positive Negative
Positive 429 427 2
Negative 451 3 448
Sum 880 430 450
Abbreviations: DOAC, direct oral anticoagulant; LC-MS/MS, liquid
chromatography-tandem mass spectrometry.
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Receiver operating curves demonstrated c-values of 0.989
for the factor Xa inhibitor pad (►Fig. 2A) and 0.995 for the
thrombin inhibitor pad (►Fig. 2B). (A c-value of 0.5 indicates
that a test result is not better than chance, and a c-value of 1.0
indicates a “perfect” test result.)
Intention-to-Analyze Evaluation
The intention-to-analyze evaluation conﬁrmed the results of
the per-protocol evaluation (►Tables 6–8). There were no
differences of these results with those of the per-protocol
evaluation.
Center Effects
Relevant differences in visual evaluation of the factor Xa
inhibitor and thrombin inhibitor pads were not detected
between centers. For the factor Xa inhibitor pad, 24/880
(2.8%) colors were interpreted falsely (►Supplementary
Table S3 [available in the online version], p¼0.518; chi-
square test). The thrombin inhibitor pad colors were inter-
preted falsely in 5 of 880 cases (0.7%) (►Supplementary
Table S4, available in the online version). Differences be-
tween centers were not calculated because of the low
frequencies (n¼0 or n¼1) per center.
Other Findings
The urine color pad was evaluated as abnormal in three cases
and, consequently, the results were excluded from the evalua-
tion (see►Fig. 1). Sevenof451 results in theDXIgroupand3of
429 results in the DTI group were DOAC concentrations
<30 ng/mL suggesting that participants had not taken their
Table 5 Sensitivity, speciﬁcity, accuracy, negative predictive
values (NPV), positive predictive values (PPV), and kappa index
of the visual evaluation of factor Xa inhibitor pad and of
thrombin inhibitor pad (mean, 95% conﬁdence interval)
Factor Xa inhibitor
pad
Thrombin inhibitor
pad
Mean 95% CI Mean 95% CI
Sensitivity 0.962 0.941; 0.978 0.995 0.983; 0.999
Speciﬁcity 0.984 0.967; 0.993 0.991 0.978; 0.998
Accuracy 0.973 0.960; 0.982 0.993 0.985; 0.998
NPV 0.961 0.939; 0.977 0.996 0.984; 0.999
PPV 0.984 0.968; 0.994 0.991 0.976; 0.998
Kappa 0.945 0.924; 0.967 0.987 0.976; 0.997
Abbreviations: CI, conﬁdence interval; na, not available.
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Fig. 2 Receiver-operating curves (ROCs) of visual evaluation of the factor Xa inhibitor pad (A) and the thrombin inhibitor pad (B). Inlet:
magniﬁcation of the “critical” part of the ROC.
Table 6 Intention-to-analyze evaluation: visual evaluation of
the factor Xa inhibitor pad (pad 3) after incubation in urine
samples from subjects in the oral direct factor Xa inhibitor (DXI)
group and the oral thrombin inhibitor (DTI) group compared
with LC-MS/MS results
Factor Xa inhibitor pad
LC-MS/MS result DOAC Dipstick result
Positive Negative
Positive 460 442 18
Negative 445 11 434
Sum 905 453 452
Abbreviations: DOAC, direct oral anticoagulant; LC-MS/MS, liquid
chromatography-tandem mass spectrometry.
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medication; these results were nonetheless included in the
intention-to-analyze evaluation.
Discussion
The results of this study describe for the ﬁrst time a multi-
center evaluation of a rapid point-of-care test to determine if
DOACs are present in a patient’s urine sample. The accuracy
of tests for Xa and thrombin inhibitors were 97.3 and 99.3%
and sensitivities, speciﬁcities, and negative and positive
predictive values were all 95% or higher with a tendency of
higher accuracy values obtained with the thrombin inhibitor
DOAC Dipstick pad. Previously reported sensitivity and
speciﬁcity values of point-of-care devices using prothrombin
time, activated partial thromboplastin time, or diluted clot-
ting time reagents andwhole blood samples ranged between
60 and 95% for each of the two types of DOACs.18–20 The
multicenter study collected a large sample and the inter-
center variation in interpretations was low, demonstrating
the feasibility of the assay.
Strengths of this study and its results can be summarized
as follows: The test results demonstrate at least 95% correct
positive and correct negative results for both oral factor Xa
and thrombin inhibitor types of DOACs. The test is easy and
rapid to perform and the results can be interpreted by
comparison with a predeﬁned color scale. Sample collection
for the test is usually not invasive, although urine catheteri-
zation may be needed to obtain a sample from unconscious
patients. The test can be repeated if the result is unclear and
can be performed at any time without technical equipment.
If patients are unable to communicate the type of antico-
agulants/DOAC they have taken, the DOAC Dipstick may
indicate whether speciﬁc DOAC testing, such as antifactor
Xa or antithrombin laboratory tests, should be ordered.
Because antithrombin is absent in normal human urine,
the test does not interfere with heparins7 unlike most assays
using blood samples.18
How can the test be implemented into the clinical setting of
patient care based on the results presented here? Importantly,
the test result can be interpreted only in connection with the
patient’sclinical situation.Examplesofpatients inwhomtesting
may be beneﬁcial are for example, if a patient presents with a
majorhemorrhageand theDOACDipstick test result is negative,
DOACs are highly unlikely to contribute to the bleeding event.
This allowsmedical treatment to be administered immediately
without waiting for results of quantitative DOAC tests. If the
DOACDipstick test gives a positive result in a patient presenting
with major haemorrhage, then a speciﬁc antidote can be
considered immediately or after plasma DOAC levels have
been determined. In another scenario, if a patient on a DOAC
therapy requires an urgent major operative procedure and the
DOAC Dipstick test is negative, it is unlikely that the patient has
signiﬁcant DOAC concentrations in blood, and the operative
procedure may be performed as soon as indicated. However, if
the DOACDipstick test is positive, the operationmay need to be
postponed or additional blood tests have been completed to
guide thedecisionprocess. The testmaybeusedbefore epidural
anesthesia or other interventions with high bleeding risk to
identify patients with residual DOAC activity, which would put
the patient at high risk of hemorrhages. In patients with
ischemic stroke, a negative test result for both types of DOACs
may be relevant for consideration to give thrombolytic therapy.
Furthermore, the DOAC Dipstick test may conﬁrm if a patient
has stopped intaking their DOACs, which may indicate a re-
quired temporary interruption or noncompliance.
The present study has some limitations. The time since last
emptying of the urine bladder may inﬂuence the amount of
DOAC present in urine, but this issue was not speciﬁcally
considered or standardized in the present study. Although
false negative results are rare, they may occur when a patient
has taken his ﬁrst DOAC immediately before urine sampling.
Studies are ongoing to determine a correlation between blood
and urine DOAC concentration.21,22 Purple urine23 and other
abnormal urine colors24 may inﬂuence the visual assessment
of the test strip. To address this, a “urine color” test pad that
does not contain reagents was included in the dipstick device
to detect abnormal urine color and avoidmisinterpretation of
the DOAC test pads.23 The excretion of DOACs into urine is
reduced with impairment of renal function. Creatinine is also
excreted less into urine when renal function is impaired, so a
fourth test pad was added to the Dipstick device. If this pad
indicates little or no creatinine in the urine sample, then the
DOAC test result should be considered invalid.
Table 7 Intention-to-analyze evaluation: visual evaluation of
the thrombin inhibitor pad (pad 4) after incubation in urine
samples from subjects in the direct oral factor Xa inhibitor (DXI)
group and the direct oral thrombin inhibitor (DTI) group
compared with LC-MS/MS results
Thrombin inhibitor pad
LC-MS/MS result DOAC Dipstick result
Positive Negative
Positive 438 436 2
Negative 468 5 463
Sum 906 441 465
Table 8 Intention-per-protocol analysis: sensitivity, speciﬁcity,
accuracy, negative predictive value (NPV), and positive
predictive value (PPV) of visual evaluation of the factor Xa
inhibitor pad and the thrombin inhibitor pad
Factor Xa inhibitor
pad
Thrombin inhibitor
pad
Mean 95% CI Mean 95% CI
Sensitivity 0.961 0.939; 0.977 0.993 0.980; 0.999
Speciﬁcity 0.975 0.956; 0.988 0.991 0.983; 0.999
Accuracy 0.968 0.957; 0.978 0.992 0.984; 0.997
NPV 0.958 0.953; 0.975 0.994 0.981; 0.999
PPV 0.976 0.957; 0.988 0.991 0.977; 0.998
Kappa 0.936 0.913; 0.959 0.985 0.973; 0.996
Abbreviation: CI, conﬁdence interval.
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In summary, the present study shows that DOAC Dipstick
test sensitively and speciﬁcally determines the presence of
both Xa and IIa inhibitors in urine samples, if compared with
the gold standard of LC-MS/MS. The evaluation of the DOAC
Dipstick test in emergency medicine and other patient
groups is ongoing.
What is known about the topic?
• In speciﬁc patient groups rapid determination of the
presence or absence of DOAC is required to facilitate
the medical decision-making processes.
• Currently available global and point-of-care coagula-
tion assays have limitations. Speciﬁc assays are only
possible in specialized laboratories and cannot be
completed quickly enough in urgent situations.
• DOACs are excreted into urine and their presence or
absence can be determinedwithin 10minutes by a test
strip.
What does this paper add?
• This multicenter study showed that factor Xa inhibitors
(apixaban, edoxaban, rivaroxaban) and the thrombin
inhibitor dabigatran were detected with high sensitivi-
ty, speciﬁcity, and accuracy in patient urine samples
using a rapid DOAC Dipstick point-of-care test.
• The high negative and positive predictive values of the
test can be integrated into laboratory and clinical deci-
sion-making processes and may improve patient care.
Participating Centers (alphabetical order per town,
number of included patients in brackets)
Bad Krozingen, Universitätsherzzentrum, Klinik für Kar-
diologie und Angiologie II, Prof. Dr. Dietmar Trenk,
Prof. Dr. Julia Hromek, Dr. Stefan Leggewie (n¼232);
Bad Oeynhausen, Herz - und Diabeteszentrum NRW,
Klinik für Kardiologie, Prof. Dr. Cornelia Piper,
Dr. Isgandarova Potratz (n¼79); Berlin, Vivantes Klini-
kum Neukölln, Kardiologie, Prof. Dr. Harald Darius,
Dr. Lorenz Reill (n¼36); Berlin, Vivantes Klinikum im
Friedrichshain, Zentrum für Gefäßmedizin - Sprech-
stunde für Gerinnungsstörung und Hämophiliezentrum,
Priv. Doz Dr. Robert Klamroth, Dr. Cornelia Kubicek-Hof-
mann, Dr. AnaMarija Orlovic (n¼27); Berlin, Gerinnungs-
zentrum Berlin, Priv.-Doz. Dr . Christoph Sucker (n¼46);
Coburg, II. Medizinische Klinik– Innere Medizin – Kardio-
logie, Dr. Steffen Schnupp, Dr. Issameddine Ajimi,
Dr. Christian Mahnkopf, Dr. Thomas Mischke (n¼70);
Darmstadt, Klinik für Gefäßmedizin - Angiologie, Prof.
Dr Rupert Bauersachs, Priv. Doz. Dr. Jörg Herold (n¼18);
Dessau-Roßlau, Praxis für Innere Medizin, Kardiologie,
Angiologie, Dr. Frank Menzel, Frank (n¼41); Dresden,
Studienambulanz Klinische Thromboseforschung, Priv.
Doz. Dr. Jan Beyer-Westendorf, Dr. Sandra Marten,
Dr. Christiane Naue (n¼3); Dresden, Studienambulanz
der GWT – TUD GmbH, Prof. Dr. Sebastian Schellong,
Dr. Carsten Müller (n¼12); Frankfurt, CCB Studienzen-
trum GmbH, Prof. Dr. Edelgard Lindhoff-Last, Dr. Barbara
Zydek (n¼89); Freiburg, Klinik für Kardiologie und
Angiologie I, Prof. Dr Daniel Dürschmied, Dr. Roland Gie-
sen, Dr. Christoph Olivier (n¼12); Hamburg, Onkolo-
gisches Zentrum, II. Medizinische Klinik und Poliklinik,
Gerinnungsambulanz, Prof. Dr. Florian Langer, Dr. Minna
Voigtländer, (n¼16); Heidenheim, Facharztpraxis für
Innere Medizin, Schwerpunkt Hämatologie, Onkologie
und Hämostaseologie, Priv. Doz. Dr. Martin Grünewald
(n¼14); Köln, Klinik für Kardiologie und internistische
Intensivmedizin, Prof. Dr. Ingo Ahrens, Ingo, Dr. Timo
Bömicke (n¼2); Leipzig, Zentrum für Blutgerinnungs-
störungen, Dr. Ute Scholz, Dr. Michael Krause (n¼18);
Stahnsdorf, Parkkardiologie, Dr. Ulrich Wolf (n¼129);
Siegen, Zentrum für Prävention und Rehabilitation,
Dr. Ulrich Overhoff, Dr. Fabian Krämer (n¼68).
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